Exelixis (EXEL) delivered impressive results, posting net profit margins of 27%, up sharply from last year’s 17.4%. Earnings ...
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.